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Abstract. Peritoneal carcinomatosis (PC) is the most 
frequent metastatic pattern of gastric cancer and its prog-
nosis is extremely poor. PC is characterized by rich fibrosis 
and the development of obstructive disorders such as ileus, 
jaundice and hydronephrosis. Epithelial-mesenchymal tran-
sition (EMT) is one of the major causes of tissue fibrosis 
and transforming growth factor β (TGF-β) has a pivotal 
function in the progression of EMT. Protein-bound polysac-
charide K (PSK) is a biological response modifier that can 
modulate the TGF-β/Smad signaling pathway in vitro. In the 
present study, we established a fibrotic tumor model using 
human peritoneal mesothelial cells (HPMCs) and a human 
gastric cancer cell line to evaluate whether PSK attenuates 
tumor fibrosis. HPMCs exposed to PSK did not undergo the 
morphological change from a cobblestone-like pattern to a 
spindle-shape pattern normally induced by treatment with 
TGF-β. Immunofluorescence further demonstrated that PSK 
suppressed TGF-β-induced overexpression of α-SMA in the 
HPMCs. We further showed that HPMCs contributed to the 
proliferation of tumor fibrosis by using a mouse xenograft 
model. Additionally, PSK treatment of these mice significantly 
reduced the area of observable tumor fibrosis. These results 
suggest that seeded cancer cells transformed HPMCs into 
myofibroblast-like cells through their release of TGF-β in the 
microenvironment, facilitating the development of fibrous 
tumors in organs covered with HPMCs. Therefore, our study 
indicates that PSK has potential utility as an anti-fibrotic agent 
in the treatment of gastric cancer patients with PC.
Introduction
Gastric cancer is a major global health concern, with an 
estimated 989,600 new cases and more than 738,000 attribut-
able deaths in 2011 (1). Peritoneal carcinomatosis (PC) is a 
characteristic feature of gastric cancer and is a critical factor 
underlying its poor prognosis (2-4).
PC is relatively resistant to systemic chemotherapy due to 
the poor blood supply and oxygenation of cancer cells in the 
peritoneum (5). A large body of data has shown that systemic 
administration of S-1 or taxanes may be efficacious in treating 
PC. These compounds have a high sensitivity in targeting 
poorly differentiated adenocarcinoma, which is a common 
microscopic type of peritoneal tumor (6,7). Furthermore, 
when administered intravenously, some of these compounds 
are transported into the peritoneal cavity (8,9). Therefore, 
combining S-1 with intraperitoneal (i.p.) administration of 
taxanes has been proposed as an effective and feasible treat-
ment strategy for PC. Ishigami et al established a protocol of 
i.p. paclitaxel with S-1 plus intravenous paclitaxel, in which 
the median survival time (MST) was 22.5 months and the 
1-year survival rate was 78% (10). S-1 plus i.p. docetaxel also 
demonstrated a promising 1-year survival rate of 70%, with an 
MST of 16.2 months in patients with severe PC (11). However, 
these clinical outcomes have been largely unsatisfactory since 
most patients die of recurrence within 5 years. PC is charac-
terized by cancer cell infiltration and proliferation, which is 
accompanied by extensive stromal fibrosis. This results in the 
development of chemoresistance and obstructive disorders 
such as ileus, obstructive jaundice and hydronephrosis (12). 
Therefore, it is necessary to develop new treatment strategies 
to target the fibrosis in PC.
The fibrous tissue found in organs during PC is produced 
by cancer-associated fibroblasts (CAFs), which are recruited 
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from orthotopic fibroblast pools (13), bone marrow-derived 
f ibrocytes (14), and human peritoneal mesothelial 
cells (HPMCs) (15). These cells can undergo epithelial-mesen-
chymal transition (EMT) to differentiate into an extracellular 
matrix-producing myofibroblastic phenotype in the presence 
of TGF-β released from gastric cancer cells (16). Therefore, 
TGF-β signaling represents a promising potential target for 
tumor fibrosis in PC.
Protein-bound polysaccharide K (PSK; Krestin®) is 
isolated and purified from the cultured mycelium of the 
Basidiomycete Coriolus versicolor (17). PSK is considered a 
biological response modifier, and has been approved for use 
in combination with chemotherapy to prolong the survival of 
patients with gastric cancer or colorectal cancer.
PSK also appears to inhibit TGF-β signaling through 
suppression of TGF-β production, direct binding with TGF-β, 
and through acting on TGF-β receptors (18-20). Ono et al 
further reported that PSK can suppress Smad2 phosphoryla-
tion, resulting in the inhibition of EMT in the colorectal cancer 
SW837 cell line (21). Here, we investigated whether PSK could 
inhibit both the EMT-like change of HPMCs in response to 
TGF-β signaling in vitro, and the subsequent induction of 
tumor fibrosis by co-inoculum of gastric cancer OCUM-2MD3 
cells and HPMCs in vivo.
Materials and methods
Cell lines and cell culture. HPMCs were isolated from 
surgical specimens of the human omentum, as previously 
described (22). Written informed consent for use of these 
specimens, as required by the Institutional Review Board 
at Kanazawa University, Japan, was obtained from patients 
undergoing elective abdominal surgery. Small pieces of 
omentum were immediately washed extensively in phosphate-
buffered saline (PBS) and were incubated in pre-warmed 
PBS containing 0.125% trypsin/EDTA (Gibco/Invitrogen, 
USA) for 30 min at 37˚C. The suspension was then passed 
through a 100-µm pore nylon mesh (Becton-Dickinson, 
Japan) to remove undigested fragments and centrifuged at 
1,500 rpm for 5 min. The collected cells were cultured in 
RPMI-1640 medium (Gibco/Invitrogen) supplemented with 
20% heat-inactivated fetal bovine serum (FBS; Nichirei 
Bioscience Inc., Japan), 100 IU/ml penicillin, 100 mg/ml 
streptomycin (Gibco/Invitrogen), and 2 mM glutamine (Nissui 
Pharmaceutical Co. Ltd., Japan). The cells were seeded in 
gelatin-coated 75-cm2 flasks (BD BioCoat, USA) and cultured 
in 10 ml of medium at 37˚C in a humidified atmosphere of 
5% CO2 in air. Subconfluent HPMCs were trypsinized with 
0.125% trypsin/EDTA before use. HPMCs were used from 
passage 1 to 3 in all experiments.
OCUM-2MD3, a cell line derived from a human scirrhous 
gastric cancer and with high peritoneal-seeding activity, was 
kindly provided by the Department of Surgical Oncology of 
Osaka City University of Medicine. OCUM-2MD3 cells were 
seeded in 75-cm2 dishes (Becton Dickinson, Tokyo, Japan) 
and cultured in 10 ml Dulbecco's modified Eagle's medium 
(Life Technologies, Tokyo, Japan) supplemented with 10% 
heat-inactivated FBS, 100 IU/ml penicillin, 100 mg/ml strep-
tomycin, 2 mM glutamine, and 0.5 mM sodium pyruvate, at 
37˚C in a humidified atmosphere of 5% CO2 in air.
Reagents. Protein-bound polysaccharide was kindly provided 
by the Kureha Chemical Ind. Co. (Japan) and TGF-β was 
purchased from Sigma-Aldrich, Inc. (USA).
Phase contrast microscopy. HPMCs in cultures were treated 
with TGF-β1 (10 ng/ml) or both TGF-β1 and PSK (100, 
500 µg/ml) for 72 h and morphological changes were visual-
ized by phase contrast microscopy. The images were captured 
using a Nikon inverted microscope (Nikon Corp., Japan).
Immunofluorescence. For visualization of E-cadherin and 
α-SMA in the HPMCs, the cells were grown on 4-well, 
collagen type I-coated culture slides (BD BioCoat) and then 
fixed in a 1:1 mixture of methanol and acetone for 10 min. 
Briefly, the slides were immersed in methanol containing 0.3% 
H2O2 for 30 min, blocked with 3.3% normal goat serum in PBS, 
and incubated with the E-cadherin antibody (H-108, rabbit 
polyclonal IgG; diluted 1:100; Santa Cruz Biotechnology, Inc., 
USA) and α-SMA (1A4, mouse monoclonal IgG; diluted 1:100; 
DakoCytomation, Denmark) at 4˚C overnight. Following three 
PBS washes, immunoreactivity was visualized by incubating 
the sections with an anti-mouse IgG antibody conjugated with 
Alexa Fluor® 488 and an anti-rabbit IgG antibody conjugated 
with Alexa Fluor® 546 (1:400; Molecular Probes/Invitrogen, 
USA) for 1 h at room temperature. Cells were then incubated 
with Hoechst 33258 for nuclear staining for 5 min and mounted 
with propyl gallate containing phenylenediamine under glass 
coverslips. Slides were observed with an immunofluorescence 
microscope (BX50/BX-FLA; Olympus, Japan).
Mouse xenograft model. All animal experiments were 
performed according to Kanazawa University's standard 
guidelines. Female immunocompromised BALB/c-nu/nu mice 
(4-6 weeks old; Charles River Laboratories Inc., Japan) with 
an average body weight of 20 g were maintained under sterile 
conditions and used for all in vivo experiments. OCUM-2MD3 
cells were co-cultured with an equivalent number of HPMCs, 
and a total of 5x106 cells in 100 µl of RPMI-1640 was then 
subcutaneously injected into the dorsal side of each mouse on 
day 0. Mice were then divided into two groups: i) mice given 
normal chow (control, n=10) and ii) mice given chow mixed 
with 1% PSK from day 1 (PSK, n=10). The PSK concentration 
within the chow was adjusted to be at a dose of approximately 
1 g/kg body weight/day, which was 1.5-fold higher than the 
clinical dose of PSK (3 g/day) estimated by the surface area 
normalization method (23). Mice were allowed unrestricted 
access to water and to the standard or mixed chow. On day 15, 
the animals were sacrificed, and the tumors were harvested. 
Tumor specimens were collected for immunohistochemical 
examination.
Histological and immunohistochemical examination. Tumor 
specimens were fixed in 10% neutral-buffered formalin and 
embedded in paraffin. Sections were stained with hematoxylin 
and eosin and Azan. To analyze fibrosis, Azan (blue)-stained 
areas were measured on a video display (magnification, 
x200) in a blinded manner using a QuickGrain digital image 
analyzer (Inotech, Hiroshima, Japan). Two sections were 
selected randomly from each sample and three fields from each 
section were evaluated; samples from 10 mice in each group 
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were examined. To evaluate α-SMA expression, the sections 
were immunostained with an α-SMA antibody (1A4, mouse 
monoclonal IgG, diluted 1:100; DakoCytomation, Japan) at 
4˚C overnight, and treated with EnVision reagent (Dako Co., 
Japan) for visualization.
Statistical analysis. All data are expressed as mean ± SD. 
Statistical analyses were conducted using SPSS statistical 
software, version 11.0 (SPSS, Inc., USA). Comparisons of drug 
effects were carried out using the Student's t-test. A p-value 
of <0.05 was considered to indicate a statistically significant 
difference.
Results
Effect of PSK on the morphological change in HPMCs 
following treatment with TGF-β1. Control HPMCs exhibited 
a polygonal and cobblestone-like growth pattern, whereas 
HPMCs treated with TGF-β1 adopted the spindle-shaped 
morphological characteristic of fibroblasts. Pretreatment with 
PSK blocked these morphological changes induced by TGF-β1 
in a concentration-dependent manner (Fig. 1).
Immunofluorescence examination. Expression of E-cadherin 
and α-SMA were evaluated by indirect immunostaining and 
confocal microscopy. In the absence of TGF-β1, HPMCs did 
not express α-SMA in the cytoplasm. Treatment with TGF-β1 
induced cytoplasmic α-SMA expression, a recognized compo-
nent of EMT change. Pretreatment of HPMCs with PSK prior 
to TGF-β1 administration prevented this EMT-like change 
(Fig. 2).
Histological and immunohistochemical examination of the 
xenograft tumors. Xenograft tumors resulted from the inocula-
tion of BALB/c-nu/nu mice with a suspension of OCUM-2MD3 
cells and HPMCs contained many α-SMA-positive cells and 
a large amount of collagen fibers. Administration of PSK 
to these mice yielded a reduction in the number of α-SMA-
positive cells and a decreased amount of collagen fibers 
(Fig. 3A). To semi-quantitatively evaluate the degree of tumor 
fibrosis, we examined the fibrotic areas in each tumor sample. 
Azan staining revealed a significant difference in the degree of 
fibrosis in the PSK group compared with the control (p<0.01; 
Fig. 3B).
Discussion
The source of CAFs has not been fully elucidated. However, 
orthotopic fibroblasts and bone marrow-derived cells may 
function as myofibroblasts during EMT. In line with these 
findings, we previously reported that bone marrow-derived 
fibrocytes can contribute to tumor proliferation and fibrosis in 
gastric cancer (14).
In this present study, we demonstrated that HPMCs trans-
formed into myofibroblast-like cells following exposure to 
TGF-β, and that these cells contributed to tumor-associated 
fibrosis. We previously demonstrated that HPMCs promoted 
fibrosis in a mouse xenograft model when co-inoculated with 
MKN45 cells (15). Together, these results suggest that HPMCs 
have a latent ability to function as CAFs and induce fibrosis 
in the tumor microenvironment in multiple cancer cell types.
Although orthotopic cancer-associated fibroblasts cross-
talk with gastric cancer cells to enhance tumor progression, 
free cancer cells in the intraperitoneal cavity could produce 
peritoneal fibrous tumors in the absence of orthotopic fibro-
blasts. In PC of gastric cancer, seeded cancer cells attach to 
HPMCs and transform them into myofibroblast-like cells by 
releasing TGF-β. Spindle-shaped HPMCs can then facilitate 
Figure 1. Representative image of morphological changes in HPMCs. (Upper left) HPMCs cultured in control medium. (Upper middle) HPMCs cultured in 
medium containing 100 µg/ml of PSK. (Upper right) HPMCs cultured in medium containing 500 µg/ml of PSK. (Lower left) HPMCs cultured in medium 
containing 10 ng/ml of TGF-β. (Lower middle) HPMCs cultured in 10 ng/ml of TGF-β and 100 µg/ml of PSK. (Lower right) HPMCs cultured in 10 ng/ml 
of TGF-β and 500 µg/ml of PSK. HPMCs cultured in each condition for 72 h were visualized by phase contrast microscopy at magnification, x200. HPMCs, 
human peritoneal mesothelial cells; PSK, protein-bound polysaccharide K.
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Figure 3. (A) Macroscopic views of mouse xenograft tumors. (Left panels) Xenograft tumors inoculated with OCUM-2MD3 cells and HPMCs contained much 
fibrous stroma showing blue color by Azan staining and many α-SMA-positive cells. (Right panels) Subcutaneous tumors in mice treated with PSK revealed 
little fibrous stroma and a small number of α-SMA-positive cells. (B) The fibrous area was measured semi-quantitatively. The PSK treatment group showed a 
significant low ratio of fibrosis when compared with the control (PSK not treated) group (p<0.01). HPMCs, human peritoneal mesothelial cells; PSK, protein-
bound polysaccharide K; H.E. hematoxylin and eosin. 
Figure 2. Representative photomicrographs of HPMCs, labeled with antibodies to E-cadherin (red) and α-SMA (green). TGF-β-treated HPMCs showed 
increased expression of α-SMA, whereas both TGF-β and PSK-treated HPMCs showed almost equal expression of α-SMA when compared with the control. 
HPMCs, human peritoneal mesothelial cells; PSK, protein-bound polysaccharide K.
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adhesion of cancer cells to the basement membrane and subse-
quently infiltrate the basement membrane as CAFs together 
with cancer cells. This concept is in agreement with the fact 
that PC can develop in any organ covered by HPMCs.
TGF-β is regarded as one of the key molecules responsible 
for the differentiation of a variety of precursor cells to a myofi-
broblastic phenotype (24). Our results revealed that HPMCs 
also adopt an elongated spindle-shaped morphology from their 
normal cobblestone-like growth pattern, and exhibit overex-
pression of α-SMA when exposed to TGF-β. This supports 
the notion that TGF-β secreted from OCUM-2MD3 cells 
transformed HPMCs into myofibroblasts within the microen-
vironment of our co-inoculated mouse model, leading to the 
promotion of tumors with a fibrous stroma.
The control of TGF-β signaling is required for the inhibi-
tion of organ fibrosis during PC, and for decreasing cancer 
invasiveness and metastasis. PSK is known to suppress 
TGF-β signal transduction through inhibition of Smad2 phos-
phorylation (21). We now demonstrated that PSK inhibited 
TGF-β-induced EMT-like change in HPMCs, and that fibrosis 
in xenograft tumors of PSK-treated mice was significantly 
reduced. Previous reports have shown that a TGF-β neutral-
izing antibody and a TGF-β receptor kinase inhibitor can both 
suppress EMT and reduce stromal fibrosis (25,26). However, 
the long-term clinical use of these agents may lead to major 
complications due to the likelihood of adverse effects from 
interference with the many important roles of TGF-β in 
normal tissues (27).
Previously, PSK has been thought to contribute to the main-
tenance of nutrition and immune strength in cancer patients 
during chemotherapy. As such, PSK has been approved for use 
in combination with chemotherapy to prolong the survival of 
patients with gastric or colorectal cancer. The effectiveness of 
PSK as a postoperative adjuvant for immunochemotherapy has 
been demonstrated by a meta-analysis (28). Here, the hazard 
ratio of 5-year survival was 0.88 (95% confidence interval: 0.79-
0.98, p=0.018), verifying that chemotherapy + PSK enhanced 
the survival of patients with curatively resected gastric cancer. 
These randomized clinical trials were conducted to examine 
the effectiveness of postoperative adjuvant immunochemo-
therapy compared with chemotherapy alone.
At present, S-1 is the standard agent for adjuvant chemo-
therapy for stage II and III patients with curative resected 
gastric cancer in Japan (29,30). The Hokuriku-Kinki Immuno-
chemotherapy Study Group on Gastric Cancer is undertaking 
a clinical trial of S-1 alone versus S-1 plus PSK for curatively 
resected stage II and IIIA gastric cancer (31). It is expected 
that the S-1 plus PSK group will demonstrate longer survival 
times than the S-1 alone group in those patients with perito-
neal recurrence.
To date, PSK has been widely used clinically in combina-
tion with chemotherapy without the observation of any serious 
side-effects. Therefore, it may hold promise as an anti-fibrotic 
agent for the treatment of gastric cancer patients with PC.
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